Skip to main content
Year archive

Haemato AG — 2021 filings

All 17 regulatory filings released by Haemato AG (HAEK) in 2021, sourced directly from the official regulator.

17 Filings
2021 Period
2021 filings (17)
Filing Released Lang
HAEMATO AG reports figures for the 3rd quarter of 2021: Further increase in revenue and earnings as well as confirmation of revenue and earnings expectations for 2021
Earnings Release 9M 2021
2021-11-18 English
HAEMATO: HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
M&A Activity
2021-10-25 English
HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
Regulatory Filings
2021-10-25 English
Half-yearly financial statements 2021
Interim / Quarterly Report H1 2021
2021-10-07 English
Half-yearly financial statements 2021
Interim / Quarterly Report H1 2021
2021-10-07 German
Konzernabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
Annual Report FY 2020
2021-09-17 German
Konzernabschluss zum Geschäftsjahr vom 01.01.2019 bis zum 31.12.2019
Audit Report / Information FY 2019
2021-09-09 German
HAEMATO AG announces preliminary figures for Q2 2021: Increase in Q2 revenue by 41% and EBIT by 596% compared to the same quarter last year.
Earnings Release H1 2021
2021-08-11 English
Annual financial statements
Annual Report FY 2020
2021-06-02 English
Annual financial statements 2020
Annual Report FY 2020
2021-06-02 German
HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million.
Earnings Release Q1 2021
2021-05-31 English
HAEMATO AG proposes dividend payment
Notice of Dividend Amount
2021-05-04 English
According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million
Earnings Release FY 2020
2021-04-21 English
HAEMATO AG successfully completes capital increase
Capital/Financing Update
2021-03-29 English
HAEMATO AG plans cash capital increase to finance private label business
Share Issue/Capital Change
2021-03-24 English
HAEMATO AG: HAEMATO PHARM GmbH as a subsidiary of HAEMATO AG receives a special approval according to 11 Abs. 1 MPG
Regulatory Filings
2021-03-23 English
HAEMATO AG: Patrick Brenske to be the sole member of the Executive Board of HAEMATO AG in the future
Board/Management Information
2021-02-01 English